Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts - PubMed
6 hours ago
- #Targeted Therapy
- #Prostate Cancer
- #Theranostics
- Radiopharmaceutical therapy (RPT) is a promising innovation in oncology that involves radioactive elements coupled with targeting vectors.
- Theranostic approaches pair diagnostic and therapeutic RPTs targeting the same molecule, enabling selective radiation delivery to cancer cells.
- Understanding cell-surface target biology and molecular mechanisms is crucial for developing and clinically using RPT agents.
- Key topics discussed include PSMA-targeted imaging and therapy for prostate cancer, using PET and SPECT for patient selection and treatment monitoring.
- Theranostics faces challenges but aims to improve treatment selection, predict response and toxicity, and expand to other tumor types beyond prostate cancer.
- Advances in target discovery, novel radiopharmaceutical design, and translational research may optimize efficacy, reduce toxicity, and broaden RPT applications.
- Healthcare systems need strategies to overcome barriers and provide broader access to RPT innovations in clinical and research settings.